DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-357/S-019

Bristol-Myers Squibb
Attention: Warren C. Randolph
Director, FDA Liaison and Global Strategy Unit
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Mr. Randolph:

Please refer to your supplemental new drug application dated February 15, 2000, received February 15, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for GLUCOPHAGE® (metformin hydrochloride tablets)

We acknowledge receipt of your submissions dated February 24, June 22, August 9, September 1, November 16, and December 8 and 13, 2000.

This supplemental new drug application provides for the use of Glucophage for the treatment of type 2 diabetes in pediatric patients (ages 10-16 years).

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted December 13, 2000).

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999). For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-357/S-019." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your postmarketing study commitment in your submissions dated November 16 and December 13, 2000. This commitment is listed below.

A single-dose pharmacokinetic study with Glucophage in pediatric (12-16 years of age) and adult populations.

Protocol Submission:	Within 3 months of the date of this letter
Study Start:	Within 3 months of the date of this letter
Final Report Submission:	Within 17 months of the date of this letter

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Protocol", "Postmarketing Study Final Report", or "Postmarketing Study Correspondence."**

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Jena Weber, Regulatory Project Manager, at (301) 827-6422.

Sincerely,

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine
Drug Products (HFD-510)
Office of Drug Evaluation II
Center for Drug Evaluation and Research